ImmunityBio Gains Crucial European Market Access for Bladder Cancer Therapy
Published on 02/21/2026 at 10:29 | Redaktion boerse-global.de
ImmunityBio has achieved a significant regulatory milestone in Europe, securing conditional marketing authorization from the European Commission for its therapy, ANKTIVA. This approval opens a substantial new market for the company and is expected to accelerate its commercial rollout. The key question now is how swiftly the biopharmaceutical firm can translate this authorization into tangible sales and distribution.
The European Commission granted conditional approval for ANKTIVA (nogapendekin alfa inbakicept) this week. It is authorized for use in combination with Bacillus Calmette-Guérin (BCG) for adult patients diagnosed with BCG-unresponsive, non-muscle invasive bladder cancer (NMIBC) of the carcinoma in situ (CIS) type, with or without accompanying papillary tumors. Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
